Navigation Links
InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer
Date:9/14/2009

LOS ALTOS, Calif., Sept. 14 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today that Linda Slanec Higgins, PhD has been named Chief Operating Officer. Since late 2007, Dr. Higgins has served as InteKrin's Chief Scientific Officer after joining the Company earlier that year. Over the past two years, Dr. Higgins has had increasingly broad operational and strategic responsibility in key areas including CMC and dosage form development, Regulatory Affairs, Corporate Development and Product Development.

"Linda's contributions to InteKrin's progress have been extraordinarily impactful and decisive," said Denny Lanfear, InteKrin Chief Executive. "By large measure, her leadership and capabilities have allowed us to move INT131 forward in many dimensions over the past two plus years and successfully surmount the considerable challenges confronting privately funded development stage companies."

"I am very pleased to have contributed to the advancement of this important therapeutic," said Dr. Higgins. "We at InteKrin look forward to completing our Phase 2b efforts and moving on into Phase 3."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, thereby enabling the separation of PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-
'/>"/>

SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer
2. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
3. InteKrin Therapeutics Announces $20 Million Series C Financing
4. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
5. Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406
6. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009
7. Oxygen Biotherapeutics, Inc. Posts Latest Blog by CEO Chris Stern
8. Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference
9. New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary, Helsinn Therapeutics (U.S.) Inc.
10. Cell Therapeutics, Inc.s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
11. Reportlinker Adds Autoimmune Disease Therapeutics Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... In recognition of Veteran’s Day, Discount Labels ... a local organization that provides services to veterans and ... on a couple hundred acres in the hills of ... class fishing, hunting, hiking, horseback riding, 4-wheeling, skeet shooting, ... ago to support U.S. Service men and women, police ...
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... December 22, 2014 7,178 small business ... of Black Friday shopping and opted instead to join ... education company, for their 5th annual “Black Friday Boot ... just $7 to attend the 5 hour online training ... promptly donated to support two Central Texas based charities ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 Luxury Linen ... Community Partners of Dallas to provide logistics and ... Dallas-based company, Peacock Alley has a long history of giving ... The additional sponsors of this year's Toy Drive were Whataburger® ... to give back than the holidays. Providing gifts to children ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. Ms. Foley is recognized with ... largest, most-recognized networking organization of professional women in the ... Association of Professional Women is a powerfully vibrant networking ... Chapters. , “As a nurse, I felt like I ...
Breaking Medicine News(10 mins):Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2
... , IRVINE, Calif., July 21 Masimo ... and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced the ... System, a revolutionary new sensor system that offers the performance ... cost-effectiveness and environmentally-green advantages of a reusable sensor. The new ...
... PHOENIX, July 21 What do moving and health have in ... to helping women has selected House to Home Services, LLC, a moving company ... , , , ... Janice Montana, president and CEO, House to Home Services, LLC.) , ...
... LEE, N.J., July 21 The Neutraceutical Company, LLC (TNC -- ... agreement for exclusive rights to direct market a remarkable new extract ... in multiple ways for centuries. This new, 100% natural product is ... aimed at helping people cope with everyday health concerns. , ...
... , OKLAHOMA CITY, July 21 ... been selected by R&D Magazine to receive the 2009 ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090721/DA49239 ) , ... in the fitting and ongoing management of prosthetic device users. This ...
... , , , MONROVIA, ... a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today ... Administration (FDA) Division of Bioresearch Monitoring that the restrictions of the "integrity ... been removed. The removal of the integrity hold enables the FDA ...
... , , MINEOLA, N.Y., July 21 ... rebranding operation to better represent the organization while educating about the ... , The new marketing material and ... is in Your Hands" pertaining to taking an active stance in ...
Cached Medicine News:Health News:Masimo Receives FDA Clearance for New Rainbow(R) Resposable(TM) Sensor System 2Health News:Masimo Receives FDA Clearance for New Rainbow(R) Resposable(TM) Sensor System 3Health News:Masimo Receives FDA Clearance for New Rainbow(R) Resposable(TM) Sensor System 4Health News:Masimo Receives FDA Clearance for New Rainbow(R) Resposable(TM) Sensor System 5Health News:House to Home Services is Selected as a Unique Health Provider 2Health News:The Neutraceutical Company Announces Powerful New 'Feel-Good' Product 2Health News:Orthocare Innovations Receives Prestigious R&D 100 Award for Computerized Prosthesis Alignment System 2Health News:Orthocare Innovations Receives Prestigious R&D 100 Award for Computerized Prosthesis Alignment System 3Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 2Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 3Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 4Health News:Review of STAAR's Application for the Visian(R) Toric Implantable Collamer(R) Lens by FDA to Resume 5Health News:The Maurer Foundation for Breast Health Education Launches Integrated Rebranding Operation 2
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
(Date:12/19/2014)... IRVINE, Calif. , Dec. 19, 2014 /PRNewswire/ ... today that Siddhartha Kadia, Ph.D. has joined the ... and Chief Executive Officer and a director of ... high-precision laboratory testing, evaluation and analytical services to ... Prior to joining Evans Analytical Group, ...
(Date:12/19/2014)... Dec. 19, 2014   Hospira, Inc. (NYSE: ... injectable drugs and infusion technologies, today announced that the ... Healthcare Conference on Wednesday, Jan. 14, 2015, in ... to begin at 10:30 a.m. Pacific time on Wednesday, ... interested parties through a live audiocast accessible via the ...
Breaking Medicine Technology:Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... ... December 2 DermaGen AB - part of the,Karolinska Development ... AB has received promising results from a,clinical Phase I/IIa study. ... atopic dermatitis. Atopic dermatitis is a chronic,inflammatory skin disease where ...
... , ROCKVILLE, Md., Dec. 2 Novavax, Inc. (Nasdaq: ... first stage of a two-stage pivotal Phase II study evaluating ... particle (VLP) pandemic influenza vaccine. Novavax is conducting this ... registration of the vaccine in Mexico and potentially other countries. ...
Cached Medicine Technology:Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 2Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 3Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis 4NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 2NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 3NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico 4
... (gadopentetate dimeglumine) injection was introduced in 1988, ... contrast-enhanced magnetic resonance imaging (MRI). It became ... in MRI. Today, the product is still ... head, neck and body. MAGNEVIST is used ...
... injection is a nonionic, iodinated, low-osmolar ... Introduced in the U.S. in 1995, ... Europe, ULTRAVIST today is used ... established a positive clinical experience in ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
Forceps with round handle, straight...
Medicine Products: